Skip to main content

COVID-19 Resources

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.cdc.gov/coronavirus

Get the latest research information from NIH: https://www.covid19.nih.gov

Grant Details

Grant Number: 5R01CA192402-04 Interpret this number
Primary Investigator: Etzioni, Ruth
Organization: Fred Hutchinson Cancer Research Center
Project Title: Estimating Overdiagnosis in Cancer Screening Studies
Fiscal Year: 2018


Abstract

DESCRIPTION (provided by applicant): Project Summary/Abstract Millions of US men and women undergo screening for early cancer detection every year. Overdiagnosis, or the detection by screening of cases that would never become clinically diagnosed, is now recognized as the greatest potential harm of screening. This presents an especially difficult clinical dilemma in breast cancer, where screening detects many in-situ tumors, and in prostate cancer, where latent cases are highly prevalent in older age groups. Overdiagnosed cases cannot be helped by treatment and overtreatment of these cases carries a high price in terms of patient morbidity and economic costs. Knowledge about overdiagnosis is critical for well-formed screening policies and for well-informed patient decision making. However, overdiagnosis depends on screening practices and personal factors and many published studies are biased or do not apply to populations that differ from those used for estimation. The objective of this work is to advance knowledge about how to validly estimate overdiagnosis and to provide concrete information about overdiagnosis associated with specific cancer screening settings so as to inform screening policy development and clinical decision making. In our first aim we will conduct a simulation study to identify acceptable approaches and key characteristics of valid overdiagnosis studies. Lessons from this aim will be applied in our second aim, which will adapt established population models to estimate overdiagnosis rates associated with breast and prostate cancer screening under different screening policies and for different population subgroups defined by patient and tumor characteristics. These estimates will be made available to policy makers and clinicians via our third aim, which will develop online calculators to present relevant and useful information about overdiagnosis to these groups. Our study team of statisticians, breast and prostate cancer modelers and clinicians includes experts in simulation modeling, prominent clinical researchers and leaders in policy development for breast and prostate cancer screening. This work will move the field forward to a point of greater consensus about how to estimate overdiagnosis and what to tell policy makers and clinicians who have been tasked with shared and informed decision making. The knowledge generated by this application will lead to sound screening policies and better- informed clinical decisions and should provide a valuable quantitative tool in the ongoing battle to improve the balance of benefit and harm associated with cancer screening.



Publications

Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
Authors: Gulati R. , Psutka S.P. , Etzioni R. .
Source: The Journal of urology, 2019 11; 202(5), p. 936-943.
EPub date: 2019-10-09.
PMID: 31112106
Related Citations

Estimating the frequency of indolent breast cancer in screening trials.
Authors: Shen Y. , Dong W. , Gulati R. , Ryser M.D. , Etzioni R. .
Source: Statistical methods in medical research, 2019 04; 28(4), p. 1261-1271.
EPub date: 2018-02-05.
PMID: 29402176
Related Citations

Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials.
Authors: Ryser M.D. , Gulati R. , Eisenberg M.C. , Shen Y. , Hwang E.S. , Etzioni R.B. .
Source: American journal of epidemiology, 2019-01-01; 188(1), p. 197-205.
PMID: 30325415
Related Citations

Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality.
Authors: Duffy S.W. , Etzioni R. , Sasieni P. .
Source: Evidence-based medicine, 2017 04; 22(2), p. 76.
EPub date: 2017-02-22.
PMID: 28228386
Related Citations

Missteps in Current Estimates of Cancer Overdiagnosis.
Authors: Lee C.I. , Etzioni R. .
Source: Academic radiology, 2017 02; 24(2), p. 226-229.
EPub date: 2016-11-25.
PMID: 27894707
Related Citations

A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden.
Authors: Gulati R. , Etzioni R. .
Source: European urology, 2017 01; 71(1), p. 53-54.
EPub date: 2016-04-16.
PMID: 27090976
Related Citations

Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
Authors: Gulati R. , Feuer E.J. , Etzioni R. .
Source: American journal of epidemiology, 2016-07-15; 184(2), p. 140-7.
EPub date: 2016-06-29.
PMID: 27358266
Related Citations

Active Surveillance for Ductal Carcinoma in Situ: Shining Light Into the Modeling Abyss.
Authors: Etzioni R. , Gulati R. .
Source: Journal of the National Cancer Institute, 2016 May; 108(5), .
EPub date: 2015-12-17.
PMID: 26683406
Related Citations

Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them.
Authors: Etzioni R. , Gulati R. .
Source: Journal of the National Cancer Institute, 2016 Mar; 108(3), .
EPub date: 2015-11-18.
PMID: 26582245
Related Citations

The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model.
Authors: Birnbaum J. , Gadi V.K. , Markowitz E. , Etzioni R. .
Source: Annals of internal medicine, 2016-02-16; 164(4), p. 236-43.
EPub date: 2016-01-12.
PMID: 26756332
Related Citations




Back to Top